Medgadget.comPrecision Oncology: Interview with Presage Biosciences Founder Dr. James OlsonMedgadget.comDr. Olson: The trial is enrolling patients with either newly diagnosed lymphomas who have not yet received treatment or relapsed lymphoma previously…
Evans syndrome associated with sterile inflammation of the central nervous …7thSpace Interactive (press release)Although treatment with rituximab was effective to normalize erythrocyte and thrombocyte levels in her peripheral blood, it failed to damp…
Medscape |
What’s Hot at ASH 2013?
Medscape This study directly compared the new agent obinutuzumab (Gazyva) against the standard therapy rituximab (Rituxan), and both were administered in combination with chlorambucil (abstract 6). Top-line results from this trial recently released by the … |
Science CodexRadioactive antibodies successfully kill HIV-infected cellsScienceBlog.com (blog)Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated…
|
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 55(th …
Wall Street Journal Title: “Phase II Study of Anti-CD19 Antibody Drug Conjugate (SAR3419) in Combination with Rituximab: Clinical Activity and Safety in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma” (Abstract #4395). — Poster session #624: Dec. |
Antibodies improving Ebola survivabilityDVIDSEbola virus research is conducted in maximum containment Biosafety Level 4, or BSL-4, laboratories, where investigators wear positive-pressure suits and breathe filtered air as they work. Here, scientists Ge…
Women Citizen |
Synthetic Antibodies Created With Coated Nanoparticles
Women Citizen To create these “synthetic antibodies,” the researchers used carbon nanotubes – hollow, nanometer-thick cylinders made of carbon that naturally fluoresce when exposed to laser light. In the past, researchers have exploited this phenomenon to create … |
A Health Care Portolio for the Ages: CheckupMotley FoolAfter a predefined interim analysis, idelalisib showed a large and statistically significant improvement to progression-free survival when added to rituximab as a second-line treatment. Those resul…
|
Visterra secures exclusive patent license for promising dengue virus …
News-Medical.net “We are very pleased to license these promising dengue virus antibodies from MIT, and we are focused on rapidly developing a product candidate for this global and devastating infectious disease for which there is currently no preventive or therapeutic … Visterra Acquires Antibody Family from MITGenetic Engineering News Visterra gets $8M to advance flu drug, acquires dengue drugBoston Business Journal (blog) |
Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against …Business Wire (press release)CAMBRIDGE, Mass.–(BUSINESS WIRE)–Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, t…